Why the study?
Does maternal administration of terbutaline improve fetal ventricular rate and cardiac function in fetal congenital complete heart block?
Does maternal administration of terbutaline improve fetal ventricular rate and cardiac function in fetal congenital complete heart block?
Maternal administration of terbutaline may be effective in improving fetal congenital heart block and preventing heart failure in utero.
May warrant consideration in select fetal heart block cases; leaves open need for controlled trials to confirm benefit.
We report a case of fetal congenital heart block treated with maternal administration of beta-sympathomimetics. The case was diagnosed as fetal complete heart block associated with maternal anti-Ro/SS-A antibody at 22 weeks of gestation. By fetal sonography, the ventricular rate was revealed to be 60 beats/min and mild cardiomegaly was shown. We initiated maternal administration of a sympathomimetic, specifically terbutaline, to prevent fetal heart failure. An increase in the fetal ventricular rate and an improvement in cardiac function were both achieved during the treatment. A viable infant was delivered by an elective cesarean section without complications at term. Maternal administration of the beta-adrenergic agent terbutaline is suggested to be effective for improving fetal congenital heart block in order to prevent heart failure in utero.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: